India · Delayed Price · Currency is INR NSE:NEPHROPLUS Statistics
Total Valuation
NSE:NEPHROPLUS has a market cap or net worth of INR 60.58 billion. The enterprise value is 57.12 billion.
| Market Cap | 60.58B |
| Enterprise Value | 57.12B |
Important Dates
The next confirmed earnings date is Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NSE:NEPHROPLUS has 100.56 million shares outstanding. The number of shares has increased by 17.70% in one year.
| Current Share Class | 100.56M |
| Shares Outstanding | 100.56M |
| Shares Change (YoY) | +17.70% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 14.71% |
| Owned by Institutions (%) | 24.21% |
| Float | 28.59M |
Valuation Ratios
The trailing PE ratio is 69.80 and the forward PE ratio is 36.72. NSE:NEPHROPLUS's PEG ratio is 0.86.
| PE Ratio | 69.80 |
| Forward PE | 36.72 |
| PS Ratio | 5.75 |
| PB Ratio | 5.43 |
| P/TBV Ratio | 6.08 |
| P/FCF Ratio | 53.30 |
| P/OCF Ratio | 26.05 |
| PEG Ratio | 0.86 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.23, with an EV/FCF ratio of 50.26.
| EV / Earnings | 67.11 |
| EV / Sales | 5.43 |
| EV / EBITDA | 24.23 |
| EV / EBIT | 39.81 |
| EV / FCF | 50.26 |
Financial Position
The company has a current ratio of 2.80, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.80 |
| Quick Ratio | 2.48 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.33 |
| Debt / FCF | 0.70 |
| Interest Coverage | 2.78 |
Financial Efficiency
Return on equity (ROE) is 9.04% and return on invested capital (ROIC) is 15.08%.
| Return on Equity (ROE) | 9.04% |
| Return on Assets (ROA) | 7.03% |
| Return on Invested Capital (ROIC) | 15.08% |
| Return on Capital Employed (ROCE) | 11.85% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 4.59M |
| Profits Per Employee | 371,011 |
| Employee Count | 2,294 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 20.77 |
Taxes
In the past 12 months, NSE:NEPHROPLUS has paid 248.75 million in taxes.
| Income Tax | 248.75M |
| Effective Tax Rate | 22.62% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 684.92 |
| 200-Day Moving Average | 613.07 |
| Relative Strength Index (RSI) | 28.16 |
| Average Volume (20 Days) | 703,127 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:NEPHROPLUS had revenue of INR 10.53 billion and earned 851.10 million in profits. Earnings per share was 8.63.
| Revenue | 10.53B |
| Gross Profit | 4.08B |
| Operating Income | 1.50B |
| Pretax Income | 1.10B |
| Net Income | 851.10M |
| EBITDA | 2.29B |
| EBIT | 1.50B |
| Earnings Per Share (EPS) | 8.63 |
Balance Sheet
The company has 4.26 billion in cash and 797.07 million in debt, with a net cash position of 3.46 billion or 34.39 per share.
| Cash & Cash Equivalents | 4.26B |
| Total Debt | 797.07M |
| Net Cash | 3.46B |
| Net Cash Per Share | 34.39 |
| Equity (Book Value) | 11.16B |
| Book Value Per Share | 111.27 |
| Working Capital | 5.40B |
Cash Flow
In the last 12 months, operating cash flow was 2.33 billion and capital expenditures -1.19 billion, giving a free cash flow of 1.14 billion.
| Operating Cash Flow | 2.33B |
| Capital Expenditures | -1.19B |
| Depreciation & Amortization | 787.89M |
| Net Borrowing | -2.15B |
| Free Cash Flow | 1.14B |
| FCF Per Share | 11.30 |
Margins
Gross margin is 38.77%, with operating and profit margins of 14.26% and 8.08%.
| Gross Margin | 38.77% |
| Operating Margin | 14.26% |
| Pretax Margin | 10.45% |
| Profit Margin | 8.08% |
| EBITDA Margin | 21.74% |
| EBIT Margin | 14.26% |
| FCF Margin | 11.38% |
Dividends & Yields
NSE:NEPHROPLUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -17.70% |
| Shareholder Yield | -17.70% |
| Earnings Yield | 1.43% |
| FCF Yield | 1.88% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:NEPHROPLUS is 836.00, which is 38.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 836.00 |
| Price Target Difference | 38.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 19.65% |
| EPS Growth Forecast (3Y) | 46.79% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |